Weekly Research Analysts’ Ratings Updates for Celcuity (CELC)

Celcuity (NASDAQ: CELC) recently received a number of ratings updates from brokerages and research firms:

• 7/15/2026 – Celcuity had its “buy” rating reaffirmed by Craig Hallum. They now have a $178.00 price target on the stock.
• 7/15/2026 – Celcuity had its price target raised by HC Wainwright from $145.00 to $155.00. They now have a “buy” rating on the stock.
• 7/15/2026 – Celcuity had its “outperform” rating reaffirmed by Citigroup Inc..
• 7/15/2026 – Celcuity had its price target raised by Citizens Jmp from $160.00 to $177.00. They now have a “market outperform” rating on the stock.
• 6/4/2026 – Celcuity was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
• 6/3/2026 – Celcuity had its price target lowered by Craig Hallum from $189.00 to $171.00. They now have a “buy” rating on the stock.
• 6/3/2026 – Celcuity had its “buy” rating reaffirmed by Guggenheim.
• 6/3/2026 – Celcuity had its price target lowered by Wells Fargo & Company from $183.00 to $166.00. They now have an “overweight” rating on the stock.
• 6/3/2026 – Celcuity had its price target lowered by HC Wainwright from $185.00 to $145.00. They now have a “buy” rating on the stock.
• 6/2/2026 – Celcuity was given a new $155.00 price target by Leerink Partners.
• 5/28/2026 – Celcuity was given a new $160.00 price target by Macquarie Infrastructure Holdings, LLC.
• 5/28/2026 – Celcuity had its “market outperform” rating reaffirmed by Citigroup Inc..

Insiders Place Their Bets

In other Celcuity news, Director David Dalvey sold 25,000 shares of the company’s stock in a transaction on Monday, May 4th. The stock was sold at an average price of $140.68, for a total value of $3,517,000.00. Following the completion of the transaction, the director owned 65,000 shares in the company, valued at $9,144,200. This represents a 27.78% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Richard E. Buller sold 9,000 shares of the firm’s stock in a transaction on Monday, May 4th. The shares were sold at an average price of $140.46, for a total value of $1,264,140.00. Following the sale, the director directly owned 6,760 shares of the company’s stock, valued at approximately $949,509.60. This represents a 57.11% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 13.33% of the company’s stock.

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.